Advances in Parkinsonism: Biochemistry, Physiology, TreatmentWalther Birkmayer, Oleh Hornykiewicz |
Contents
Addresses of contributors | 9 |
List of main abbreviations | 15 |
21 | 36 |
Copyright | |
22 other sections not shown
Common terms and phrases
abnormal agonists akinesia amantadine amine amino acids amphetamine animals anticholinergic apomorphine areas Barbeau basal ganglia benserazide biochemical Birkmayer Brain Res Catecholamine caudate nucleus cells cerebellar cholinergic clinical cortex decarboxylase inhibitor decrease deprenil dopa Dopamine dopaminergic dosage dose of L-dopa drugs duration dyskinesias dystonia effect of L-dopa enzyme extrapyramidal Figure frequency function Fuxe GABA GAD activity globus pallidus glutamate haloperidol Hornykiewicz improvement increase inhibition injection innervation L-dopa L-dopa therapy L-dopa treatment lesions levels Levodopa McGeer mechanism metabolism mg/kg monkeys Monoamine muscle neostriatum nerve nervous Neurology neurons nigrostriatal normal observed on-off parkin Parkinson's disease parkinsonian patients parkinsonian tremor parkinsonism pathway patients with Parkinson's peripheral Pharmacol phenomenon piribedil plasma postural tremor Psychiat putamen receptors reserpine response rigidity sensory side-effects stimulation striatal striatum substantia nigra symptoms syndrome Table thalamus therapeutic Treatment of Parkinson's treatment with L-dopa tyrosine hydroxylase Yahr